Brentuximab Vedotin Demonstrates Significant Activity in B-Cell Lymphoma

Share this content:

the Cancer Therapy Advisor take:

According to a new study published in the journal Blood, researchers from various institutions across the United States have found that brentuximab vedotin has significant activity in patients with refractory diffuse large B-cell lymphoma (DLBCL) and a variety of CD30 expression levels.

For the open-label, phase 2 study, researchers sought to investigate the efficacy of brentuximab vedotin in patients with relapsed or refractory CD30-positive non-Hodgkin lymphoma (NHL), and in this planned subset analysis, researchers included 49 patients with DLBCL and 19 patients with other B-cell NHLs.

Results showed an objective response rate of 44% for patients with DLBCL. Specifically, 17% achieved a complete remission with a median duration of 16.6 months as of this analysis.

Although all patients that experienced a response had quantifiable CD30 levels, researchers found no statistical correlation between objective response and CD30 expression level. In addition, patients with other B-cell NHLs also responsed to brentuximab vedotin (8 complete responses, 2 partial responses).

In regard to safety, observed adverse events were similar to known toxicities of the anti-CD30 antibody-drug conjugate. When brentuximab vedotin was used in combination with rituximab, similar activity was observed with a well tolerated safety profile.

Brentuximab Vedotin Demonstrates Significant Activity in B-Cell Lymphoma
Brentuximab vedotin has significant activity in patients with refractory diffuse large B-cell lymphoma.
This phase 2, open-label study evaluated efficacy of brentuximab vedotin, an anti-CD30 antibody-drug conjugate, in relapsed/refractory CD30-positive NHL. Significant activity with brentuximab vedotin was observed in refractory DLBCL and responses occurred across a range of CD30 expression.
READ FULL ARTICLE From Mdlinx

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters